EOD Snippets on Market

Sunidhi
"In your prosperity lies our success"

30 October 2025

INDEX	Up/Down	Percentage	Points	Index Closing
S&P BSE SENSEX	▼	-0.70%	-592.67	84404.46
NIFTY 50	▼	-0.68%	-176.05	25877.85
S&P BSE MIDCAP	▲	0.00%	0.77	47306.37
S&P BSE SMALLCAP	▼	-0.06%	-30.05	54,092.25
S&P BSE 500	▼	-0.47%	-178.46	37420.19

Index	Open	High	Low	Close	52 W High	52 W Low
SENSEX	84,750.90	84,906.95	84,312.65	84,404.46	85,290.06	71,425.01
NIFTY	25,984.40	26,032.05	25,845.25	25,877.85	26,104.20	21,743.65

SENSEX Gainers	7	NIFTY Gainers	12
SENSEX Losers	23	NIFTY Losers	38

Exchange	Advances	Declines	Advance/Decline Ratio	Unchanged
BSE	1954	2404	0.81	267
NSE	1137	1461	0.78	67

Top 5 SENSEX Drivers				Top 5 Gainers & Losers (X – Sensex)			
Gainers	(%)	Losers	(%)	Gainers	(%)	Losers	(%)
LARSEN AND TOUBRO LIMITEI	0.91%	Bharti Airtel Limited	-1.64%	AMINEX PUBLIC LIMITED COM	29.53%	CAPTAIN TECHNOCAST LIMITE	-10.29%
BHART ELECTRONICS LTD	0.66%	POWER GRID CORPORATION O	-1.30%	BENGAL STEEL INDUSTRIES LTD	25.00%	BOTHRA METALS AND ALLOYS	-9.92%
ULTRATECH CEMENT LIMITED	0.46%	TECH MAHINDRA LIMITED	-1.27%	ATISHAY LIMITED	19.99%	BILLWIN INDUSTRIES LIMITED	-9.88%
MARUTI SUZUKI INDIA LIMITE	0.42%	INFOSYS LIMITED	-1.10%	AARTI SURFACTANTS LIMITED	19.72%	DCM FINANCIAL SERVICES LIM	-9.66%
TATA MOTORS LIMITED	0.27%	BAJAJ FINSERV LIMITED	-1.05%	CHEMCRUX ENTERPRISES LIMITED	19.53%	AA PLUS TRADELINK LIMITED	-9.60%

Top 5 NIFTY Drivers				Top 5 Gainers & Losers (X – Nifty)			
Gainers	(%)	Losers	(%)	Gainers	(%)	Losers	(%)
COAL INDIA LTD	1.49%	DR.REDDY'S LABORATORIES L	-3.89%	EUROTEX INDUSTRIES AND EX	20.00%	OCCL	-17.87%
LARSEN AND TOUBRO LIMITEI	0.74%	CIPLA LIMITED	-2.59%	HB STOCKHOLDINGS	19.99%	LE TRAVENUES TECHNOLOGY	-16.20%
BHARAT ELECTRONICS LIMITE	0.66%	HDFC LIFE INSURANCE COMPA	-1.93%	KEYNOTE FINANCIAL SERVICE	19.92%	ZIM LABORATORIES .	-10.64%
HINDALCO INDUSTRIES LIMITI	0.60%	Bharti Airtel Limited	-1.63%	THE SANDESH	19.52%	SHAILY ENGINEERING PLASTIC	-10.21%
NESTLE INDIA LIMITED	0.54%	POWER GRID CORPORATION O	-1.30%	ASSOCIATED ALCOHOLS & BRI	17.49%	UNITED HEAT TRANSFER	-8.31%

Note: - The above calculations are based on Closing Prices and not on Last Traded Prices.

PB Fintech shares zoomed 7.4% on robust Q2 insurance growth:

Shares of PB Fintech, which owns and operates Policybazaar and Paisabazaar, were in demand today with the scrip rising up to 7.4% to hit an intraday high of ₹1,849.90 per share after the company reported a strong September quarter (Q2FY26) performance, driven by robust growth in its insurance segment. The company's operating revenue rose 38% Y-o-Y to ₹1,614 crore, while profit after tax (PAT) surged 165% Y-o-Y to ₹135 crore, translating to a margin of 8%. Adjusted Ebitda jumped 180% Y-o-Y to ₹156 crore, with margins improving from 5% to 10%. The total insurance premium for the quarter stood at ₹7,605 crore, up 40% Y-o-Y and 15% sequentially, led by a 44% jump in new protection business – including health and term insurance – with health insurance premiums alone up 60%. On an annualised basis, the total insurance premium reached ₹30,420 crore, reflecting a 40% Y-o-Y rise, while core online insurance premium grew 34%. Renewal and trail revenue on a 12-month rolling basis came in at ₹774 crore, up 39% Y-o-Y, led by a 47% increase in the insurance segment.

Dilip Buildcon share price rallied 6.1% in trade today on securing Contract:

Construction firm Dilip Buildcon share price was in demand today with the scrip rising as much as 6.1% to hit an intraday high of ₹512.45 per share after the company announced that it has secured a contract worth ₹307.08 crore. In an exchange filing, Dilip Buildcon said, "We are pleased to inform you that the Company has been awarded a Back-to-Back subcontract by the ISC Projects Pvt. Ltd. in the Chakradharpur Division of South Eastern Railway." Under the terms of the contract, Dilip Buildcon will undertake comprehensive construction and infrastructure works for the Barpali loading bulb project at Kusara, under the jurisdiction of Dy CE/Con/Jharsuguda, Chakradharpur Division, South Eastern Railway.

BHEL shares surged 6.8% on strong Q2 results:

Shares of Bharat Heavy Electricals (BHEL) rallied 6.8% to ₹262.40 after reporting strong Q2FY26 results The company's revenues grew 14% year-on-year (YoY) to ₹7,512 crore. With a drop in Employee benefits and other expenses by 260 and 310 bps YoY, EBITDA more-than-doubled to ₹580 crore vs ₹275 crore last year. With operational performance and rise in other income, profit after tax grew 3.5 times YoY to ₹368 crore vs ₹97 crore last year. BHEL received orders worth ₹35,375 crore during the quarter, taking the total order book to ₹2.2 trillion, 80% or ₹1.75 trillion of order book from power segment and rest is Industry segment including exports. The company received a maiden order for the Kavach system fromIndian Railways for design, development and installation of KAVACH equipment, in locomotives and at trackside locations on a 36 km section of the SW Railways.

Sagility share price surged 13.7%, hit all-time high on healthy Q2:

Shares of Sagility, surged 13.7% to hit a fresh record high (all-time high) of ₹57.90 after the company reported strong earnings for the September quarter of FY26, driven by healthy revenue growth and a sharp improvement in profitability. For the quarter ended September 30, 2025, Sagility posted revenue of ₹1,658.5 crore ($189.4 million), marking a robust 25.2% year-on-year (Y-o-Y) increase, or 20% in constant currency (CC) terms. Organic revenue growth stood at 16% Y-o-Y (11.1% in constant currency). The company's adjusted Ebitda came in at ₹435.2 crore ($49.8 million), up 25.6% Y-o-Y, with margins steady at 26.2%. Adjusted profit after tax (PAT) surged 84% Y-o-Y to ₹301 crore ($34.5 million), while basic earnings per share (EPS) jumped 113.8% Y-o-Y to ₹0.54.

Dr Reddy's Labs fell 5.6% after firm gets NON for semaglutide in Canada:

Shares of Dr Reddy's Laboratories hit a five-month low of ₹1,181.60, plunging 5.6% on the BSE in Thursday's intra-day trade after the company received a Notice of Non-Compliance (NON) from Pharmaceutical Drugs Directorate, Canada, regarding its Abbreviated New Drug Submission (ANDS) for Semaglutide Injection. Dr Reddy's has informed the stock exchanges that it has received a NON from the Pharmaceutical Drugs Directorate, Canada, regarding its ANDS for Semaglutide Injection. The NON outlines requests for additional information and clarifications on specific aspects of the submission. "We will submit a response at the earliest and well within the stipulated time period. We remain confident in the quality, safety and comparability of our proposed product and remain committed to making this important therapy available to patients in Canada and other markets at the earliest," said the company in an exchange filing.

Disclosures and Disclaimer

Disclosures and Disclaimers: This Report is published by Sunidhi Securities & Finance Limited (hereinafter referred to as "Sunidhi") SEBI Research Analyst Registration Number: INH000001329 for private circulation. Sunidhi is a registered Stock Broker with National Stock Exchange of India Limited, BSE Limited and Metropolitan Stock Exchange of India Limited in cash, derivatives and currency derivatives segments. It is also having registration as a Depository Participant with CDSL.

Sunidhi has other business divisions with independent research teams separated by Chinese walls, and therefore may, at times, have different or contrary views on stocks and markets.

Sunidhi or its associates has not been debarred / suspended by SEBI or any other regulatory authority for accessing / dealing in securities Market. Sunidhi or analyst or his relatives do not hold any financial interest in the subject company. Associates may have such interest in its ordinary course of business as a distinct and independent body. Sunidhi or its associates or Analyst do not have any conflict or material conflict of interest at the time of publication of the research report with the company covered by Analyst.

Sunidhi or its associates / analyst has not received any compensation / managed or co-managed public offering of securities of the company covered by Analyst during the past twelve months. Sunidhi or its associates has not received any compensation or other benefits from the company covered by Analyst or third party in connection with the research report. Analyst has not served as an officer, director or employee of subject company and Sunidhi / analyst has not been engaged in market making activity of the subject company.

Analyst or his relatives do not hold beneficial ownership of 1% or more in the subject company at the end of the month immediately preceding the date of publication of this research report. Sunidhi or its associates may have investment positions in the stocks recommended in this report, which may have beneficial ownership of 1% or more in the subject company at the end of the month immediately preceding the date of publication of this research report. However, Sunidhi is maintaining Chinese wall between other business divisions or activities. Analyst has exercised due diligence in checking correctness of details and opinion expressed herein is unbiased.

This report is meant for personal informational purposes and is not be construed as a solicitation or financial advice or an offer to buy or sell any securities or related financial instruments. While utmost care has been taken in preparing this report, we claim no responsibility for its accuracy. Recipients should not regard the report as a substitute for the exercise of their own judgment. Any opinions expressed in this report are subject to change without any notice and this report is not under any obligation to update or keep current the information contained herein. Past performance is not necessarily indicative of future results. This report accepts no liability whatsoever for any loss or damage of any kind arising out of the use of all or any part of this report.

Each recipient of this document should make such investigations as they deem necessary to arrive at an independent evaluation of an investment in the securities of the companies referred to in this document (including the merits and risks involved), and should consult their own advisors to determine the merits and risks of such an investment.

The information in this document has been printed on the basis of publicly available information, internal data and other reliable sources believed to be true, but we do not represent that it is accurate or complete and it should not be relied on as such, as this document is for general guidance only. Sunidhi or any of its affiliates/ group companies shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. Sunidhi has not independently verified all the information contained within this document. Accordingly, we cannot testify, nor make any representation or warranty, express or implied, to the accuracy, contents or data contained within this document. While Sunidhi endeavors to update on a reasonable basis the information discussed in this material, there may be regulatory, compliance, or other reasons that prevent us from doing so. Neither Sunidhi nor its directors, employees or affiliates shall be liable for any loss or damage that may arise from or in connection with the use of this information.

Sunidhi Securities & Finance Ltd. – Research Analyst – INH000001329

Kalpataru Inspire, Unit.1, 8th floor, Opp. Grand Hyatt Hotel, Santacruz East, Mumbai-400055

Bombay Stock Exchange (BSE)	National Stock Exchange of India Ltd (NSE)	Metropolitan Stock Exchange of India Limited (MSEI)
Registration no. INZ000169235	Registration no. INZ000169235	Registration no. INZ000169235
Compliance Officer Name:	Mr. Mahesh Desai	Phone No: 9122-66771777